Elevated serum sialyl Lewis X-i antigen levels in non-small cell lung cancer with lung metastasis.
To evaluate the relationship between serum levels of sialyl Lewis X-i antigen and lung metastasis in patients with non-small cell lung cancer (NSCLC), we measured the serum level of the antigen in 299 patients with untreated locally advanced or metastatic NSCLC. Before treatment, serum levels of sialyl Lewis X-i antigen were significantly higher in patients with lung metastasis than in those without lung metastatis (p = 0.0001). Of 201 patients without lung metastasis at the time of primary diagnosis, 121 patients died between July 1987 and December 1995. Serum levels of sialyl Lewis X-i antigen in 21 patients who developed lung metastasis during the period were significantly higher than those in 100 patients who did not develop lung metastasis (p = 0.0171). Our results suggested that sialyl Lewis X-i antigen might be a good indicator for the presence or development of lung metastasis, and it might provide clinical information about the management of patients with NSCLC.
Satoh
H
H
Department of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Japan. hirosato@md.tsukuba.ac.jp
Ishikawa
H
H
Kamma
H
H
Yamashita
Y T
YT
Takahashi
H
H
Ohtsuka
M
M
Hasegawa
S
S
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011863:Radioimmunoassay; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D015996:Survival Rate
D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen